- Company receives grant to fund clinic for marginalized, underserved NYC communities
- New clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the service
- Program’s clinicians will receive specialized training
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital (https://ibn.fm/zyerA).
Part of Northwell Health, the largest healthcare system in New York State, Lenox Hill Hospital serves marginalized and underserved communities on the Upper East Side of Manhattan, New York. The hospital is working to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States.
“It’s time for psychedelic medicine to climb down from the ivory tower and into the community,” said Cybin chief clinical officer Dr. Alex Belser. “We are honored to support this program at Lenox Hill Hospital to start a low-cost/no-cost psychedelic clinic for marginalized and underserved communities in New York.”
One of Northwell Health’s flagship hospitals, Lenox Hill Hospital is a 450-bed, acute-care facility on Manhattan’s Upper East Side. The clinical program at the hospital’s Outpatient Center for Mental Health is dedicated to addressing health inequities by prioritizing care for marginalized and underserved populations. The new psychedelic treatment clinic, funded and supported in part by Cybin, will offer treatment with no out-of-pocket cost for individuals who would otherwise be unable to afford the service; the clinic will also offer psychedelic treatments to frontline healthcare workers who are having difficulty dealing with COVID-19.
In addition, the program’s clinicians will receive specialized training in MDMA-, ketamine- and tryptamine-assisted psychotherapy, as well as in EMBARK, a transdiagnostic psychedelic psychotherapy model. Created by Belser and his colleague Bill Brennan, EMBARK offers a wide range of flexibility. The model can be adapted to address a range of clinical indications and populations.
“Lenox Hill Hospital is excited by the potential of these modalities for the treatment of previously intractable conditions such as severe depression, chronic PTSD and OCD,” said David Roane, MD, chair of psychiatry at Lenox Hill Hospital. “With this grant from Cybin, Lenox Hill Hospital aims to become one of the first hospital-based clinical sites offering psychedelic medicine in the country and is dedicated to addressing health inequities by prioritizing care for marginalized and underserved populations. In particular, people of color are greatly underrepresented in psychedelic research studies, and our team is committed to inclusive recruitment of patients.”
Cybin is a leading ethical biopharmaceutical company and is working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics to address a multitude of mental health issues. The company operates in the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental-health disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork
